ARKG241108C24000
- 1.45
- +0.31+27.19%
ARK Genomic Revolution ETF Newsroom
Adaptive Biotechnologies Raises FY2024 Sales Guidance From $140.00M-145.00M to $143.00M-145.00M
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $77
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
Here Are the Major Earnings After the Close Today
Where Ionis Pharmaceuticals Stands With Analysts
Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Buy on Veracyte, Raises Price Target to $44
Veracyte Analyst Ratings
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
Recursion Pharmaceuticals EPS of -$0.34 Misses by $0.01, Revenue of $26.1M Misses by $3.73M
Veracyte Non-GAAP EPS of $0.33 Beats by $0.16, Revenue of $115.86M Beats by $6.03M
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
A Glimpse of Intellia Therapeutics's Earnings Potential
Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
Nurix Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Here's the Major Earnings Before the Open Tomorrow
Beam Falls After Fatality in Gene Editing Trial